Premarin scientific update |
|
 |
|
J Pediatr Adolesc Gynecol. 2004 Dec;17(6):389-92.
Derman O, Gold MA.
Hacettepe University School of Medicine, Ankara, Turkey.
Poland's syndrome and premature ovarian failure.
A study on Poland’s syndrome and premature ovarian failure. A female patient having Poland's Syndrome with left amastia, scoliosis, and left Sprengel deformity was evaluated during the test. The study found out that premature ovarian failure associated with Poland’s syndrome might be coincidental.
A 19-year-old female with Poland's Syndrome with associated left amastia, scoliosis, and left Sprengel deformity developed secondary amenorrhea from premature ovarian failure. Her menarche was at 13 years of age, and periods were regular and monthly until 15 years of age when her periods suddenly stopped. Her hormonal evaluation was significant for elevated FSH (46.5 mIU/ml) and LH (28.5 mIU/ml), and low estradiol (23 pg/ml). Anti-ovarian antibody level was less than 2 units (normal < 4 units). Her chromosomes were 46XX, by both standard karyotype and by fluorescence in situ hybridization. On transabdominal and transvaginal ultrasonography, ovaries were not visualized, the uterus was of normal size and anteverted and both kidneys were normal. The patient began hormone replacement therapy with conjugated estrogen (Premarin) 0.625 mg po daily and progestin (Provera) 5 mg on days 20 to 25. Because of menopausal symptoms, she was switched to a combination oral contraceptive (OC) with 20 mcg ethinyl estradiol that was eventually increased to 30 mcg. Her menopausal symptoms (hot flashes and sweating) improved on the continuous 30 mcg ethinyl estradiol combination OC. Following a comprehensive review of the literature, this is the first reported case of Poland's Syndrome associated with premature ovarian failure; however, this association may be coincidental.
Gynecol Endocrinol. 2005 Apr;20(4):227-35.
Augoulea A, Mastorakos G, Lambrinoudaki I, Christodoulakos G, Creatsas G.
Second Department of Obstetrics and Gynecology, Aretaieion Hospital, University of Athens, Greece.
Role of postmenopausal hormone replacement therapy on body fat gain and leptin levels.
A study to determine the effect of postmenopausal hormone replacement therapy on body fat gain and leptin levels. It is a common fact that women gain fat during menopause. Obesity caused during this period is associated with elevated serum leptin levels.
During menopause women tend to gain body fat. The increase in adiposity seems to be a consequence of the decline in endogenous estrogens and the reduced energy expenditure. The role of post-menopausal hormone replacement therapy (pHT) in modulating visceral obesity is controversial. Some studies have shown that pHT has no effect on body weight while in other studies pHT increased body weight. Leptin is an adipocyte-derived hormone and its levels reflect the amount of adipose tissue. Obesity is associated with elevated serum leptin levels. The effect of pHT on leptin levels is also controversial. In some studies pHT increased leptin levels while other studies have not confirmed this increasing effect. The major problem encountered during administration of hormone therapy seems to be the timing of pHT initiation which is a strong confounder on the effect of pHT on leptin levels in postmenopausal women.
Premarin description...
|
|
Drug category:Menopause and Premenstrual Syndrome relief agents
 Premarin scientific update
|
|
My Basket